Modern cancer immunotherapy relies heavily on APCs like DCs. Traditional viral-based DC modification faces safety risks and manufacturing complexity, while custom mRNA-based reprogramming offers a non-viral alternative—enabling transient, efficient expression of therapeutic genes to engineer personalized anti-tumor immune responses.
Creative Biolabs' service delivers next-gen cellular therapeutics and personalized vaccines via optimized mRNA and advanced delivery systems. It bypasses traditional limitations, providing exceptional safety and speed, and specializes in engineering DCs/APCs with superior antigen presentation, enhanced cytokine secretion, and potent T-cell priming.
Discover How We Can Help - Request a Consultation
The core of our service lies in utilizing highly engineered mRNA to meticulously control the cellular machinery of immune cells. This powerful platform enables two distinct yet complementary strategies: DC Maturation Enhancement (ex vivo or in vivo) and In Situ Cell Fate Conversion (in vivo).
DC maturation determines the ultimate quality of the T-cell response. Creative Biolabs specializes in using multi-component mRNA mixes to direct this process toward maximum anti-tumor potency.
This precise combination shifts the DC transcriptional profile toward an antiviral-like state, which is more effective at overcoming tumor tolerance than the bacterial-like program induced by earlier mixes. It results in DCs that secrete higher levels of IL-12, enabling durable priming and differentiation of tumor-specific CD8+ T cells into long-lived memory populations (TSCM and TCM).
Fig.1 In vivo reprogramming of tumor cells to dendritic cells.1
Our streamlined, end-to-end workflow is designed for transparency and efficiency, ensuring high-quality outputs suitable for preclinical studies.
Conduct custom IVT mRNA synthesis with necessary modifications (e.g., Pseudouridine, ARCA cap).
Formulate optimized LNPs, lipoplexes/polyplexes, or prepare an injectable LNP-Hydrogel system for in vivo delivery projects.
Perform optimized non-viral delivery (typically electroporation for ex vivo DCs) to maximize transfection efficiency while preserving cell viability.
Conduct flow cytometry (surface marker expression, maturation status), cytokine ELISAs (IL-12p70, IFN-γ, IL-10), and gene expression profiling (qPCR/RNA-seq).
Co-culture reprogrammed DCs with naive or tumor-specific T cells, followed by proliferation, memory (TSCM, TCM) differentiation, and tumor cell killing assays.
As an excellent seller, I understand that as a biology expert, you require precision, speed, and safety to accelerate your lead. Creative Biolabs' Custom mRNA based Dendritic Cell Reprogramming Service is the definitive solution for next-generation immunotherapy, engineered exactly to your project's unique specifications.
Non-Viral Safety Guarantee:
Ensure transient, non-integrative genetic modification, eliminate insertional mutagenesis risks associated with viral vectors, and significantly streamline regulatory pathways.
Custom Transcript Synthesis (10x Efficiency):
Provide IVT mRNA optimized with Pseudouridine and ARCA capping, achieving 10-fold higher translation efficiency and enhanced stability for sustained therapeutic protein expression.
Precision Reprogramming for High Potency:
Customize multi-component mRNA mixes to drive antiviral-like transcriptional programs in DCs, dramatically boosting IL-12 secretion and T-cell priming efficacy.
Advanced Localized Delivery Systems:
Offer project-specific LNPs, lipoplexes, or proprietary Hydrogel-LNP Depot Technology for efficient, sustained localized in vivo delivery, enabling TME modulation and in situ cell fate conversion.
Durable T-Cell Memory Induction:
Validated high-function DCs efficiently prime naive CD8+ T cells, driving differentiation into long-lived populations (e.g., TSCM, TCM) to underpin persistent anti-cancer immunity.
Versatile Transient Cell Engineering:
Deliver tailored mRNA templates and protocols for efficient, non-toxic transient expression of CARs/TCRs in T/NK cells, accelerating target screening and safety assessment of cell therapy candidates.
Experience the Creative Biolabs Advantage - Get a Quote Today
Traditional cytokine cocktails yield DCs with limited T-cell priming and rapid functional decay. Our mRNA approach programs DCs to an enhanced antiviral-like state, enabling higher sustained IL-12 secretion and superior TSCM/TCM differentiation—control unachievable with external cytokines alone.
mRNA is non-integrating and naturally degraded within days, eliminating insertional mutagenesis risks associated with viral vectors. It offers a cleaner, safer profile for clinical translation.
Yes. Our versatile platform adapts TF mRNA and LNP technology to reprogram tumor cells, fibroblasts, etc., into immunogenic APCs for TME modulation. Contact our team to discuss project feasibility.
We support both. Our mRNA synthesis and electroporation enable efficient, non-toxic transient CAR/TCR expression in T/NK cells, accelerating preclinical screening with high safety margins. Validated templates and protocols are provided.
Creative Biolabs is your strategic partner in advanced immunotherapy, specializing in non-viral genetic engineering of immune cells. From designing high-potency mRNA for DC vaccines to delivering advanced delivery systems for in situ cell fate conversion, we provide validated solutions to accelerate your research from concept to clinic. We are committed to advancing cellular therapy and enabling safer, more effective cellular therapeutics.
Contact Our Team for More Information and to Discuss Your Project
Reference
